What's being said on the web about "qnexa obstructive sleep apnea"

  • NASDAQ: VVUS) today announced that, from the two study assessed the obstructive sleep apnea (OSA) treatment of the safety and Qnexa ®, an investigational drug, efficacy positive results. Wei Washi company recently completed Phase III ... [view original]

  • VIVUS Announces Positive Results From Phase 2 Study of Qnexa in Obstructive Sleep Apnea VIVUS, Inc. today announced positive results from a phase 2 study evaluating the safety and efficacy of Qnexa®, an investigational drug, ... [view original]

  • VIVUS Announces Positive Results From Phase 2 Study Of Qnexa In Obstructive Sleep Apnea. Share/Bookmark Tags: Articles / News, body-weight, health, healthcare law, law, parallel-group ... [view original]

  • ... and methods of use, including the treatment of Syndrome X, a common multisymptomatic disorder often found in obese patients, and the treatment of other conditions that can be alleviated with loss of body weight, such as sleep apnea. ... [view original]

  • Related News. Vivus says mid-stage study shows its obesity drug candidate Qnexa reduced sleep apnea symptoms. January 7th, 2010 Vivus says Qnexa helped treat sleep apnea in studyMOUNTAIN VIEW, Calif. — Vivus Inc. ... [view original]

  • VIVUS announced positive results from a phase 2 study evaluating the safety and efficacy of Qnexa, our investigational drug candidate, for the treatment of obstructive sleep apnea (OSA). This study demonstrated statistically significant ... [view original]

  • The study announced today demonstrated statistically significant improvement in the apnea/hypopnea index (”AHI” – a measure of the severity of sleep apnea) in patients with OSA treated with Qnexa for 28 weeks. ... [view original]

  • (Nasdaq: VVUS) today announced positive results from a phase 2 study evaluating the safety and efficacy of Qnexa®, an investigational drug, for the treatment of obstructive sleep apnea (OSA). VIVUS recently completed phase 3 development ... [view original]

  • VVUS announced positive results from a phase 2 study evaluating the safety and efficacy of Qnexa(R), an investigational drug, for the treatment of obstructive sleep apnea (OSA). VVUS recently completed phase 3 development of Qnexa for ... [view original]

  • Mountain View, California (AP) - Wei Washi company said Thursday, a clinical study shows that the weight-loss drug Qnexa facilitate treatment, to improve sleep. [view original]

  • . [view original]

  • Also in January, VVUS reported positive results from a phase II study evaluating the safety and efficacy of Qnexa, its investigational drug, for the treatment of obstructive sleep apnea (OSA). According to the report, ... [view original]

  • The company said a 28-week study involving 45 obese patients suffering ugg outlet from obstructive sleep apnea, or OSA, found that treatment with Qnexa led to a drop in the number of apnea/hypopnea events to a mean of 14 per hour of ... [view original]

  • from a phase 2 study evaluating the safety and efficacy of Qnexa®, an investigational drug, for the treatment of obstructive sleep apnea (OSA). VIVUS recently completed phase 3 development of Qnexa for the treatment of obesity and ... [view original]

  • January 201, announced positive results from a phase 2 study evaluating the safety and efficacy of Qnexa, an investigational drug, for the treatment of obstructive sleep apnea (OSA). … See the original post: ... [view original]

  • Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor for ... [view original]

  • Vivus said a 28-week Phase II clinical study of 45 obese men and women suffering from obstructive sleep apnea indicated Qnexa led to a drop in the number of apnea events to an average 14 an hour of sleep from 46 an hour. ... [view original]

  • Vivus conducted a 28-week study on 45 obese patients who were suffering from sleep apnea and obstructive sleep apnea . Treatment of Qnexa led to a significant drop in the number of apnea events for the patients. … Read more: ... [view original]

  • Obstructive Sleep Apnea Program: VVUS announced positive results from a phase II study evaluating the safety and efficacy of Qnexa, the Company's investigational drug candidate, for the treatment of obstructive sleep apnea (OSA). ... [view original]

  • The company said a 28-week study involving 45 obese patients suffering from obstructive sleep apnea, or OSA, found that treatment with Qnexa led to a drop in the number of apnea/hypopnea events to a mean of 14 per hour of sleep from 46 ... [view original]

share

Social web results for: qnexa obstructive sleep apnea

digg.com Digg_fav

    twitter Twitter_fav

      Picture results for: qnexa obstructive sleep apnea

      flickr Flickr_fav
        photobucket Photobucket_fav

          Blog results for: qnexa obstructive sleep apnea

          blogsearch.google.com Blogsearch_fav

          • Stock Alert for Vivus Inc. (VVUS) | Beacon Equity Research Obstructive Sleep Apnea Program: VVUS announced positive results from a phase II study evaluating the safety and efficacy of Qnexa, the Company's investigational drug candidate, for the treatment of obstructive sleep apnea (OSA). ...From:
          • VIVUS Announced 2nd Phase Study Results of Qnexa VIVUS announced positive results from a phase 2 study evaluating the safety and efficacy of Qnexa, our investigational drug candidate, for the treatment of obstructive sleep apnea (OSA). This study demonstrated statistically significant ...From:
          • VIVUS Announces the Issuances of Three Additional Qnexa(R) Patent.. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor for ...From:
          • VIVUS Announces Positive Results From Phase 2 Study of Qnexa in ... (Nasdaq: VVUS) today announced positive results from a phase 2 study evaluating the safety and efficacy of Qnexa®, an investigational drug, for the treatment of obstructive sleep apnea (OSA). VIVUS recently completed phase 3 development ...From:
          • VIVUS Gets 3 Patents Related to Qnexa – Stock a Moderate-Volume.. ... and methods of use, including the treatment of Syndrome X, a common multisymptomatic disorder often found in obese patients, and the treatment of other conditions that can be alleviated with loss of body weight, such as sleep apnea. ...From:

          bloglines.com Bloglines

            twingly.com Twingly

              News results for: qnexa obstructive sleep apnea

              wikio news Wikio_fav

                yahoo news YahooNews_fav

                Video results for: qnexa obstructive sleep apnea

                youtube Youtube_fav
                  truveo Truveo_fav

                    Product results for: qnexa obstructive sleep apnea

                    ebay Ebay_fav
                      amazon Amazon_fav